Equities Analysts Set Expectations for ATNM FY2026 Earnings

Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Free Report) – Analysts at HC Wainwright lifted their FY2026 EPS estimates for Actinium Pharmaceuticals in a research report issued on Tuesday, November 17th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of $0.30 per share for the year, up from their prior estimate of $0.12. HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q4 2026 earnings at ($0.22) EPS, FY2027 earnings at ($0.59) EPS and FY2028 earnings at ($0.60) EPS.

Actinium Pharmaceuticals Trading Down 1.9%

ATNM stock opened at $1.05 on Thursday. The stock has a 50-day moving average price of $1.28 and a two-hundred day moving average price of $1.13. Actinium Pharmaceuticals has a 1 year low of $0.74 and a 1 year high of $1.72. The stock has a market cap of $33.01 million, a PE ratio of -0.76 and a beta of 0.27.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Compass Financial Management LLC acquired a new stake in Actinium Pharmaceuticals in the 2nd quarter valued at approximately $588,000. Renaissance Technologies LLC lifted its stake in Actinium Pharmaceuticals by 20.7% in the 1st quarter. Renaissance Technologies LLC now owns 471,600 shares of the company’s stock valued at $469,000 after acquiring an additional 80,816 shares in the last quarter. Finally, BlackRock Inc. bought a new stake in Actinium Pharmaceuticals in the 2nd quarter valued at approximately $388,000. 27.50% of the stock is owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

(Get Free Report)

Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for patients with cancer, particularly blood cancers. Its approach combines cancer-targeting antibodies with radioactive isotopes intended to deliver radiation to specific cells. The company’s investigational programs include Iomab-B (apamistamab), an iodine-131-labeled antibody targeting CD45, developed as a conditioning treatment before a bone marrow transplant for certain patients with acute myeloid leukemia.

Recommended Stories

Earnings History and Estimates for Actinium Pharmaceuticals (NYSE:ATNM)

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.